Valuation: Roche Holding AG

Market Cap 277B 333B 296B 252B 475B 32,055B 480B 3,346B 1,297B 16,387B 1,252B 1,225B 52,592B P/E 2026 *
18.8x
P/E 2027 * 17x
Enterprise Value 287B 347B 308B 262B 494B 33,316B 499B 3,478B 1,348B 17,032B 1,301B 1,273B 54,661B EV / Sales 2026 *
4.58x
EV / Sales 2027 * 4.28x
Free-Float
88.78%
Yield 2026 *
2.9%
Yield 2027 * 2.97%

Last Transcript: Roche Holding AG

1 day+0.65%
1 week-2.66%
Current month-0.67%
1 month-0.61%
3 months+5.97%
6 months+11.79%
Current year+6.92%
1 week 353.8
Extreme 353.8
369.6
1 month 351.2
Extreme 351.2
380.6
Current year 301.2
Extreme 301.2
383
1 year 270.8
Extreme 270.8
383
3 years 229.4
Extreme 229.4
383
5 years 229.4
Extreme 229.4
439.2
10 years 209.4
Extreme 209.4
439.2
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
+0.65%-2.66% - - 333B
-0.61%-3.43%+36.07%+115.04% 1,019B
-1.02%-5.60%+35.72%+64.63% 617B
+1.11%-0.58%+12.36%+77.95% 464B
+0.34%-3.01%+61.79%+41.24% 356B
+0.88%-1.74%+21.08%+41.55% 333B
+1.11%-2.88%+11.44%+35.16% 267B
+0.33%-4.61%-6.36%+9.30% 244B
-1.04%-2.79%+35.30%+51.84% 218B
-1.87%-4.10%+28.44%+93.66% 179B
Average -0.01%-3.54%+26.20%+58.93% 410.8B
Weighted average by Cap. -0.07%-3.54%+29.17%+70.74%

Financials

2026 *2027 *
Net sales 62.69B 75.6B 67.17B 57.14B 108B 7,267B 109B 759B 294B 3,715B 284B 278B 11,923B 65.54B 79.04B 70.22B 59.74B 113B 7,598B 114B 793B 307B 3,884B 297B 290B 12,466B
Net income 14.49B 17.48B 15.53B 13.21B 24.91B 1,680B 25.14B 175B 67.96B 859B 65.61B 64.19B 2,756B 16.32B 19.68B 17.49B 14.88B 28.06B 1,892B 28.32B 198B 76.55B 967B 73.91B 72.3B 3,105B
Net Debt 10.88B 13.12B 11.65B 9.91B 18.7B 1,261B 18.87B 132B 51.01B 645B 49.25B 48.18B 2,069B 4.03B 4.86B 4.32B 3.68B 6.93B 468B 7B 48.82B 18.92B 239B 18.26B 17.87B 767B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
26-10-05 CHF 358.40 +0.73% 4,609
26-10-02 CHF 355.80 -0.84% 21,846
26-10-01 CHF 358.80 -0.55% 26,805
26-09-30 CHF 360.80 -0.55% 44,943
26-09-29 CHF 362.80 -1.47% 24,202
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
345.70CHF
Average target price
375.34CHF
Spread / Average Target
+8.57%

Quarterly revenue - Rate of surprise